Nova Eye Medical (ASX:EYE) disclosed Q1 FY27 total sales of US$6.3 million, representing 30% growth on the prior corresponding period, while recording an operating cash inflow of A$0.5 million for the quarter and confirming full-year FY27 sales guidance of US$26 million to US$31 million, excluding China.

Key Points

  • Q1 FY27 total sales reached US$6.3 million, up 30% on the prior corresponding period
  • Last twelve months sales to September 2026 totalled US$25.1 million, up 30%
  • Operating cash inflow of A$0.5 million recorded in Q1 FY27, with positive EBITDA also disclosed
  • Liquidity of A$4.1 million at 30 September 2026, comprising A$2.1 million cash and A$2.0 million undrawn debt facility
  • FY27 sales guidance of US$26 million to US$31 million (excluding China) confirmed

Q1 FY27 Sales Performance by Region

According to the filing, Nova Eye Medical recorded Q1 FY27 sales of US$5.189 million in the USA, up 25% on the prior corresponding period, while Germany contributed US$499,000, up 24%. Rest of world sales grew 44% to US$444,000. Sales excluding China totalled US$6.132 million, up 26%. China contributed US$158,000 in Q1 FY27, compared to nil in Q1 FY26, bringing total sales to US$6.290 million. The company noted that October USA sales were approximately 30% above the prior corresponding period. All Q1 FY27 figures are described as unaudited.

Last Twelve Months Revenue and Market Share

The filing disclosed that last twelve months sales to September 2026 totalled US$25.118 million, with USA last twelve months sales reaching US$19.739 million, up 29%. Germany contributed US$2.128 million over the same period, up 11%, while rest of world sales rose 72% to US$2.146 million. China last twelve months sales were US$1.106 million, up 38%. The company disclosed that the LTM growth rate accelerated from 26% at June 2026 to 30% at September 2026. The annualised revenue per sales representative in Q1 FY27 was US$1.8 million, compared with US$1.6 million in Q1 FY26.

Cash Position and Operating Cash Flow

Nova Eye Medical disclosed that cash flow from operations turned positive in Q1 FY27, with a net operating cash inflow of A$0.5 million recorded for the quarter. The company reported total liquidity of A$4.1 million at 30 September 2026, comprising A$2.1 million in cash and an A$2.0 million undrawn debt facility. The filing also stated that the company achieved positive EBITDA for the quarter. Nova Eye Medical designs and manufactures devices used by surgeons to treat patients with glaucoma, with its iTrack Advance product holding approvals and generating revenue across direct markets including the USA and Germany.